Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• History of motion sickness

• Currently suffering from migraines with at least 2 episodes during the previous 12 months

• Previous use and tolerance to triptans

Exclusion Criteria:

• Current tobacco user

• History of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease

• Family history of early myocardial infarction (first-degree relative < 45 years old at time of event)

• Constant dizziness or constant vestibular symptoms

• History of ear, nose and throat (ENT) disease, e.g. Meniere's disease

• Current treatment with propranolol or medications that would preclude use of a triptan(e.g. ergotamine)

• Major vestibular abnormality found on screening

• Testing positive on over-the-counter pregnancy test

• Taken an Monamine Oxidase (MAO) inhibitor within two weeks of testing

• Allergy or intolerance to gelatin

• Corrected visual acuity of > 20/40 O.U.

• Women who are pregnant or breastfeeding